ijmedicine

INTERNATIONAL JOURNAL OF ADVANCED MEDICINE (IJAM)

ISSN (O) : 2663 - 046X

A CrossRef Indexed Journal

DOI : 10.34300/26630451

ISSN (P) : 2663 - 0451

IC VALUE : 89.03 (2020)

International Journal of Advanced Medicine (IJAM)
Original Research Paper

Outcomes Of Covid-19 Amongst Patients With Ongoing Use Of Inhaled Corticosteroids - A Systematic Review & Meta-analysis

Syed Nazeer Mahmood, Viraj Shah, Urvish Patel, Muhammad Umair Nawaz, Narayana Varalakshmi Akula, Irina Balan, Divya Manivannan, Yelena Pleshkova, Shayaan Negit, Prarthana Desai, Richa Jaiswal, Namratha Gurram, Neel Patel, Raghvendra Tirupathi, Thoyaja Koritala

Abstract :

BackgroundThe numbers quoted by WHO for the Coronavirus disease 2019 (COVID-19) pandemic as of August 2021 were 200 million cases with over 4 million deaths globally. COVID-19 is associated with several respiratory pathologies. Inhaled corticosteroids (ICS) are used to improve lung function by reducing inflammation, edema, mucus secretion, and inhibiting various cytokine activities. However, there is limited data on the effect of ICS usage in patients with COVID-19. In this study, we aim to evaluate the association between the effectiveness of ICS and the outcomes in COVID-19 patients compared to standard COVID-19 treatment. MethodsWe followed PRISMA guidelines and MOOSE protocol for conducting the systematic review and meta-analysis comparing ICS and standard COVID-19 therapy. A search on PubMed is conducted yielding 270 articles of which 6 manuscripts are finalized for inclusion in the study. Patients with COVID-19 are identified from the studies based on confirmed positive RT-PCR tests. Hospitalization, ICU admission, and mortality are selected as the outcomes of our study. Using RevMan 5.3, we performed random-effects models to estimate the pooled effect size (pooled odds ratio), 95% confidence interval (95% CI), and heterogeneity (I2). Forest plots are obtained and p <0.05 is considered statistically significant.ResultsOf the six studies, five reported mortality. We noted a higher prevalence of mortality in patients with asthma (60.88%, 107/160) and chronic obstructive pulmonary disease (COPD) (68.46%, 382/558). The overall mortality is 7.49% (107/1428). We found that ICS use was associated with higher odds of mortality (OR=1.45 95%CI: 1.10-1.91; p=0.009, I2= 68%) amongst COVID-19 patients. In subgroup analysis, higher odds of mortality among COPD patients using ICS was noted [pooled OR: 1.52 (1.24-1.86); p<0.0001; I2=0%]. However, no significant association between ICS and mortality was observed among asthma patients. ConclusionICS is associated with increased mortality and risk for hospitalization in patients with COVID-19 as compared to standard non-steroid-based COVID-19 therapy. Future studies are needed to support the evidence of ICS discontinuation in COVID-19 patients.

Keywords :

Inhaled corticosteroids (ICS)   WHO   RT-PCR  

Cite This Article:

OUTCOMES OF COVID-19 AMONGST PATIENTS WITH ONGOING USE OF INHALED CORTICOSTEROIDS - A SYSTEMATIC REVIEW & META-ANALYSIS, Syed Nazeer Mahmood, Viraj Shah, Urvish Patel, Muhammad Umair Nawaz, Narayana Varalakshmi Akula, Irina Balan, Divya Manivannan, Yelena Pleshkova, Shayaan Negit, Prarthana Desai, Richa Jaiswal, Namratha Gurram, Neel Patel, Raghvendra Tirupathi, Thoyaja Koritala, INTERNATIONAL JOURNAL OF ADVANCED MEDICINE : Volume-8 | Issue-3 | May-2024

References :


[ Download PDF] [ Number of Downloads : 79 ]


Calendar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Disclaimer: Articles on International Journal of Advanced Medicine have been previewed and authenticated by the Authors before sending the publication for print.
The Journal, Editor and the editorial board are not entitled or liable to either justify or responsible for inaccurate and misleading data if any.
It is the sole responsibility of the Author concerned. If any queries or infringement occurs

Copyrights ©2024: International Journal of Advanced Medicine (IJAM)